109162 ⎘
Structure or type of the nucleic acid; Chemical structure of the backbone Phosphorothioates
EFFECTS OF APOLIPOPROTEIN B INHIBITION ON GENE EXPRESSION PROFILES IN ANIMALS
#2402METHOD OF TREATMENT
#2403Polynucleotide agents targeting hydroxyacid oxidase (glycolate oxidase, HAO1) and methods of use thereof
#2404TMPRSS6 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2405Oligonucleotide compositions with enhanced efficiency
#2406Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2407Modulation of huntingtin expression
#2408Compositions and methods for correcting limb girdle muscular dystrophy type 2C using exon skipping
#2409MIRNA MIMETICS AND THEIR USE IN TREATING SENSORY CONDITIONS
#2410Micro-RNA inhibitors and their uses in disease
#2411Modulation of alpha synuclein expression
#2412RNA Modulating Oligonucleotides with Improved Characteristics for the Treatment of Neuromuscular Disorders
#2413Compositions and methods for inhibition of expression of protein C (PROC) genes
#2414RNA interference mediated therapy for neurodegenerative diseases
#2415Targeting ligands
#2416COMPOSITIONS AND METHODS FOR MODULATING RNA
#2417Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2418Treatment of delta-like 1 homolog (DLK1) related diseases by inhibition of natural antisense transcript to DLK1
#2419INHIBITORS OF MIR-17-92 CLUSTER FOR ANTI-TUMOR ACTIVITY IN MULTIPLE MYELOMA AND OTHER MALIGNANCIES
#2420Compositions and methods for modulating Tau expression
#2421ANTISENSE OLIGONUCLEOTIDES FOR INDUCING EXON SKIPPING AND METHODS OF USE THEREOF
#2422Guide RNA with chemical modifications
#2423Oligonucleotide lipid nanoparticle compositions, methods of making and methods of using the same
#2424Compositions and methods for modulating TTR expression
#2425METHODS FOR MODULATING MECP2 EXPRESSION
#2426Treatment of NANOG related diseases by inhibition of natural antisense transcript to NANOG
#2427Oligonucleotide compositions and uses thereof
#2428Compositions and methods for inhibiting expression of the ALAS1 gene
#2429RNA interference mediated inhibition of catenin (cadherin-associated protein), beta 1 (CTNNB1) gene expression using short interfering nucleic acid (siNA)
#2430TARGETING OLIGONUCLEOTIDES AND USES THEREOF TO MODULATE GENE EXPRESSION
#2431Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1
#2432Antisense oligonucleotides (ODN) against SMAD7 and uses thereof in medical field
#2433Multimeric oligonucleotide compounds having non-nucleotide based cleavable linkers
#2434Oligonucleotide therapy for leber congenital amaurosis
#2435Acyl-amino-LNA and/or hydrocarbyl-amino-LNA oligonucleotides
#24362′-methoxy substituted oligomeric compounds and compositions for use in gene modulations
#2437Compositions and methods for inhibiting gene expression of factor XII
#2438Disulfide-containing alkyne linking agents
#2439LNA OLIGONUCLEOTIDES WITH ALTERNATING FLANKS
#2440Compositions for modulating expression of C9ORF72 antisense transcript
#2441Antisense conjugates for decreasing expression of DMPK
#2442LNA Gapmer Oligonucleotides Comprising Chiral Phosphorothioate Linkages
#2443Oligonucleotide compositions and methods of making the same
#2444Oligonucleotide compositions and methods of making the same
#2445METHOD FOR PREVENTION OF COLECTOMY
#2446Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2447Compounds and methods for the modulation of proteins
#2448Antisense oligonucleotides for modulating HTRA1 expression
#2449Antisense oligonucleotides for inducing exon skipping and methods of use thereof
#2450Treatment of sodium channel, voltage-gated, alpha subunit (SCNA) related diseases by inhibition of natural antisense transcript to SCNA
#2451COMPOUNDS AND METHODS FOR IMPROVED CELLULAR UPTAKE OF ANTISENSE COMPOUNDS
#2452Reducing intron retention
#2453COMPOSITIONS AND METHODS
#2454MODULATION OF HEPATITIS B VIRUS (HBV) EXPRESSION
#2455FULLY STABILIZED ASYMMETRIC SIRNA
#2456Methods for treatment of alport syndrome
#2457REVERSIR TM COMPOUNDS
#2458Methods for treating spinal muscular atrophy
#2459EGFR nucleic acids and uses thereof
#2460Methods and means of generating IL-17 associated antitumor effector cells by inhibition of NR2F6 inhibition
#2461Modulation of UBE3A-ATS expression
#2462Non-aggregating immunostimulatory oligonucleotides
#2463Modified oligonucleotides and methods for their synthesis
#2464Treatment of RNASE H1 related diseases by inhibition of natural antisense transcript to RNASE H1
#2465Treatment of fibroblast growth factor 21 (FGF21) related diseases by inhibition of natural antisense transcript to FGF21
#2466Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
#2467Modulation of alternative MDM2 splicing
#2468TREATMENT OF SODIUM CHANNEL, VOLTAGE-GATED, ALPHA SUBUNIT (SCNA) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO SCNA
#2469ANTISENSE MODULATION OF APOLIPOPROTEIN B EXPRESSION
#2470High specificity genome editing using chemically modified guide RNAs
#2471Conjugated antisense compounds and their use
#2472Hepatitis D virus (HDV) iRNA compositions and methods of use thereof
#2473Hepatitis B virus (HBV) iRNA compositions and methods of use thereof
#2474Compositions for modulating C9ORF72 expression
#2475Poly oligomer compound with biocleavable conjugates
#2476Compositions and methods for treating pancreatic cancer
#2477RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2478Antisense design
#2479Antisense design
#2480Antisense oligonucleotide modulators of serotonin receptor 2C and uses thereof
#2481ANTISENSE OLIGONUCLEOTIDES DIRECTED AGAINST CONNECTIVE TISSUE GROWTH FACTOR AND USES THEREOF
#2482Inhibitory oligonucleotide and use thereof
#2483Chiral library screen
#2484MIR-214 AS A DIAGNOSTIC AND PROGNOSTIC BIOMARKER SPECIFIC FOR ULCERATIVE COLITIS AND A MIR-214 INHIBITOR FOR TREATMENT OF SAME
#2485Organic compositions to treat Beta-ENaC-related diseases
#2486Treatment of PAR4 related diseases by inhibition of natural antisense transcript to PAR4
#2487SELECTIVE ANTISENSE COMPOUNDS AND USES THEREOF
#2488Selective Reactivation of Genes on the Inactive X Chromosome
#2489OLIGONUCLEOTIDES FOR GENOMIC DNA EDITING
#2490Oligonucleotide compositions with enhanced efficiency
#2491Modulation of AGPAT5 expression
#2492Compositions and methods for inhibiting expression of transthyretin
#2493Antisense nucleic acids
#2494Antisense-oligonucleotides as inhibitors of TGF-R signaling
#2495Modulation of prekallikrein (PKK) expression
#2496Therapeutic inhibition of lactate dehydrogenase and agents therefor
#2497Anti-TNF compounds
#2498Pharmaceutical composition for treatment of cancer comprising RNA oligonucleotide
#2499METHODS AND COMPOSITIONS FOR INHALATION DELIVERY OF CONJUGATED OLIGONUCLEOTIDE
#2500Compositions and methods for inhibition of HAO1 (Hydroxyacid Oxidase 1 (Glycolate Oxidase)) gene expression
#2501MicroRNA (miRNA) and downstream targets for diagnostic and therapeutic purposes
#2502Oligonucleotide targeted to the A20-3′ untranslated region
#2503Treatment of idiopathic pulmonary fibrosis using RNA complexes that target connective tissue growth factor
#2504RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2505Intergenic RNAS and methods for modulating gene expression and pathogenesis in
#2506RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2507KRAS nucleic acids and uses thereof
#2508ANTISENSE COMPOUNDS AND USES THEREOF
#2509Therapeutic compositions
#2510Downregulating miR-132 for the treatment of lipid related disorders
#2511Antisense design
#2512Chimeric single-stranded antisense polynucleotides and double-stranded antisense agent
#2513Methods of Inducing Exon Skipping
#2514Chiral control
#2515MODULATION OF APOLIPOPROTEIN C-III EXPRESSION
#2516METHODS AND COMPOSITIONS FOR THE SPECIFIC INHIBITION OF MYC BY DOUBLE-STRANDED RNA
#2517Methods for identifying and treating invasive/metastatic breast cancers
#2518COMPLEMENT COMPONENT C5 iRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2519MODULATION OF APOLIPOPROTEIN CIII (APOCIII) EXPRESSION
#2520Methods of Inducing Exon Skipping
#2521Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2522Post-selec modification methods
#2523Apolipoprotein C3 (APOC3) iRNA compositions and methods of use thereof
#2524Modified antimir-138 oligonucleotides
#2525Antisense oligonucleotides (ODN) against Smad7 and uses thereof in medical field
#2526Allele-specific therapy for huntington disease haplotypes
#2527COMPLEMENT COMPONENT C5 IRNA COMPOSITIONS AND METHODS OF USE THEREOF
#2528PDGF and VEGF aptamers having improved stability and their use in treating PDGF and VEGF mediated diseases and disorders
#2529ISOTOPOLOGUES OF SMAD7 ANTISENSE OLIGONUCLEOTIDES
#2530Phosphorothioate DNAzyme complexes and use thereof
#2531SCN8A splice modulating oligonucleotides and methods of use thereof
#2532RAS exon 2 skipping for cancer treatment
#2533Antiviral agent comprising RNA oligonucleotide
#2534Inhibitory Oligonucleotides for Treating Tumors
#2535Methods and compositions for treating a subject with a SMAD7 antisense oligonucleotide
#2536Polynucleotide agents targeting Serpinc1 (AT3) and methods of use thereof
#2537MicroRNA compounds and methods for modulating miR-21 activity
#2538GNAQ targeted dsRNA compositions and methods for inhibiting expression
#2539METHODS FOR DOSING AND MONITORING SMAD7 ANTISENSE OLIGONUCLEOTIDE TREATMENT USING BIOMARKER LEVELS
#2540NUCLEIC ACID LIPID PARTICLE FORMULATIONS
#2541MODULATION OF APOLIPOPROTEIN C-III (APOCIII) EXPRESSION IN LIPOPROTEIN LIPASE DEFICIENT (LPLD) POPULATIONS
#2542Antisense oligonucleotide directed removal of proteolytic cleavage sites, the HCHWA-D mutation, and trinucleotide repeat expansions
#2543COMPOSITIONS AND METHODS FOR TREATING CANCER
#2544Compositions and methods for treating pancreatic cancer
#2545TREATMENT OF GLIAL CELL DERIVED NEUROTROPHIC FACTOR (GDNF) RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO GDNF
#2546COORDINATE CONTROL OF PATHOGENIC SIGNALING BY THE MIR-130/301 FAMILY IN PULMONARY HYPERTENSION AND FIBROPROLIFERATIVE DISEASES
#2547Cationic lipid
#2548Treatment of atopic dermatitis and asthma using RNA complexes that target IL4Rα, TRPA1, or F2RL1
#2549Treatment of angiogenesis-associated diseases using RNA complexes that target ANGPT2 and PDGFB
#2550MicroRNA compounds and methods for modulating miR-122
#2551Targeting microRNAs for metabolic disorders
#2552Methods and materials for activating an internal ribosome entry site in exon 5 of the DMD gene
#2553OLIGONUCLEOTIDES FOR MODULATING TARGET RNA ACTIVITY
#2554RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA)
#2555ANTISENSE ANTINEOPLASTIC AGENT
#2556Treatment of brain derived neurotrophic factor (BDNF) related diseases by inhibition of natural antisense transcript to BDNF
#2557IMMUNOSTIMULATION BY CHEMICALLY MODIFIED RNA
#2558Multimetric oligonucleotide compounds
#2559COMPOSITIONS AND METHODS FOR MODULATING TAU EXPRESSION
#2560dsRNA for treating viral infection
#2561Oligonucleotide comprising an inosine for treating DMD
#2562Modifications for antisense compounds
#2563Preventive or therapeutic agent for fibrosis
#2564Targeting human satellite II (HSATII)
#2565Splice Switching Oligomers for TNF Superfamily Receptors and Their Use in Treatment of Disease
#2566Antisense compounds targeting apolipoprotein E receptor 2
#2567Oligonucleotides for inducing paternal UBE3A expression
#2568Exosomal loading using hydrophobically modified oligonucleotides
#2569Compositions and methods for modulating PKK expression
#2570Aptamer targeting MAGE-A3 peptide and uses thereof
#2571PHARMACEUTICAL COMPOSITIONS COMPRISING RNA AND USE FOR TREATING CANCER
#2572Composition for delivery of genetic material
#2573Antisense compounds
#2574Exon skipping technology in VCP disease
#2575SELF ASSEMBLING NUCLEIC ACID NANOSTRUCTURES
#2576Antisense oligonucleotide directed removal of proteolytic cleavage sites from proteins
#2577Compositions and methods for decreasing tau expression
#2578Compositions for modulating Ataxin 2 expression
#2579Methods for modulating Ataxin 2 expression
#2580MIR-21-3P INHIBITORS IN SKIN DISORDERS
#2581Compositions and methods for modulating growth hormone receptor expression
#2582ANTISENSE OLIGONUCLEOTIDES AND METHODS OF USE THEREOF
#2583Compositions and methods for modulating complement factor B expression
#2584Methods and compositions for treating a Serpinc1-associated disorder
#2585Antisense oligonucleotides for the treatment of Usher syndrome type 2
#2586Small interfering RNA and pharmaceutical composition and method for inhibiting galectin-12 expression and/or enhancing lipolysis containing the same
#2587Treatment of atonal homolog 1 (ATOH1) related diseases by inhibition of natural antisense transcript to ATOH1
#2588COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS
#2589Treatment of Frataxin (FXN) related diseases by inhibition of natural antisense transcript to FXN
#2590Cancer treatment
#2591Treatment of nuclear factor (erythroid-derived 2)-like 2 (NRF2) related diseases by inhibition of natural antisense transcript to NRF2
#2592Bicyclic carbocyclic nucleosides and oligomeric compounds prepared therefrom
#2593LIPID FORMULATION
#2594Treatment of age-related macular degeneration using RNA complexes that target MYD88 or TLR3
#2595Compositions and methods for inhibiting expression of RRM2 genes
#2596Antisense compounds targeting leucine-rich repeat kinase 2 (LRRK2) for the treatment of parkinsons disease
#2597Inhibition of PCSK9 through RNAI
#2598MOLECULES AND AGENTS FOR TREATING HEPATITIS B VIRUS
#2599APTAMER INHIBITING BIOLOGICAL ACTIVITY OF AUTOTAXIN BY BINDING WITH AUTOTAXIN, AND USE THEREOF
#2600Targeting microRNAS for the treatment of liver cancer
#2601Compositions comprising eicosapentaenoic acid and mipomersen and methods of use thereof
#2602LINKAGE MODIFIED GAPPED OLIGOMERIC COMPOUNDS AND USES THEREOF
#2603Small molecules that enhance the activity of oligonucleotides
#2604Methods and compositions for modulating apolipoprotein (a) expression
#2605REFILLABLE DRUG DELIVERY DEVICES AND METHODS OF USE THEREOF
#2606Serpina1 iRNA compositions and methods of use thereof
#2607Antisense compositions and methods of making and using same
#2608RNA oligonucleotide and immune system enhancer comprising same
#2609METHODS AND MEANS FOR EFFICIENT SKIPPING OF EXON 45 IN DUCHENNE MUSCULAR DYSTROPHY PRE-mRNA
#2610Modulation of gene expression and screening for deregulated protein expression
#2611Modulation of human cytomegalovirus replication by micro-RNA 132 (miR132), micro-RNA 145 (miR145) and micro-RNA 212 (miR212)
#2612Compounds and methods for enhanced cellular uptake
#2613Compositions and methods for inhibiting gene expression of LPA
#2614Spinal muscular atrophy (SMA) treatment via targeting of SMN2 splice site inhibitory sequences
#2615METHODS AND COMPOSITIONS FOR INCREASING EFFICIENCY OF TARGETED GENE MODIFICATION USING OLIGONUCLEOTIDE-MEDIATED GENE REPAIR
#2616Targeting hepatitis B virus (HBV) host factors
#2617MODULATORS OF GROWTH HORMONE RECEPTOR
#2618Modulation of TMPRSS6 expression
#2619Treatment of Collagen gene related diseases by inhibition of natural antisense transcript to a collagen gene
#2620Compositions and Methods for Selective Delivery of Oligonucleotide Molecules to Cell Types
#2621Antisense treatment of radiation induced diseases in the gastrointestinal tract
#2622RNA interference in dermal and fibrotic indications
#2623Immunostimulatory sequence oligonucleotides and methods of using the same
#2624Methods for preventing and treating chronic kidney disease (CKD)
#2625Antisense nucleic acids
#2626Targeting microRNAs for metabolic disorders
#2627Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
#2628Methods for treating cancer using nucleic acids targeting MDM2 or MYCN
#2629METHODS AND MODIFICATIONS THAT PRODUCE ssRNAi COMPOUNDS WITH ENHANCED ACTIVITY, POTENCY AND DURATION OF EFFECT
#2630Manipulating microRNA for the management of neurological diseases or conditions and compositions related thereto
#2631VASCULAR RE-MODELLING
#2632Polycomb-associated non-coding RNAs
#2633APTAMER FOR BONDING TO AUTOTAXIN AND INHIBITING BIOLOGICAL ACTIVITY OF AUTOTAXIN, AND USE FOR SAME
#2634Oligomeric compounds comprising alpha-beta-constrained nucleic acid
#2635Compositions and Methods for Modulation of SMN2 Splicing in a Subject
#2636CRISPR-BASED COMPOSITIONS AND METHODS OF USE
#2637CRISPR-based compositions and methods of use
#2638CRISPR-based compositions and methods of use
#2639Linkage modified oligomeric compounds
#2640Methods targeting miR-128 for regulating cholesterol/lipid metabolism
#2641Compositions for modulating SOD-1 expression
#2642MODULATION OF ANGIOPOIETIN-LIKE 3 EXPRESSION
#2643OLIGOMERIC COMPOUNDS AND COMPOSITIONS FOR USE IN MODULATION OF SMALL NON-CODING RNAS
#2644Oligomeric compounds and compositions for use in modulation of small non-coding RNAs
#2645Chiral design
#2646SPINAL MUSCULAR ATROPHY TREATMENT VIA TARGETING SMN2 CATALYTIC CORE
#2647SPECIFIC VIRUS-LIKE PARTICLE-CpG OLIGONUCLEOTIDE VACCINES AND USES THEREOF
#2648MODULATION OF FACTOR 11 EXPRESSION
#2649Sterile Emulsion Comprising a Stable Phosphorothioate Oligonucleotide
#2650COMPOUNDS FOR TREATING, DELAYING AND/OR PREVENTING A HUMAN GENETIC DISORDER SUCH AS MYOTONIC DYSTROPHY TYPE I (DMI)
#2651RNA modulating oligonucleotides with improved characteristics for the treatment of duchenne and becker muscular dystrophy
#2652Transthyretin (TTR) iRNA compositions and methods of use thereof for treating or preventing TTR-associated diseases
#2653RNAi agents modified at the 4′-C position
#2654Agents useful in treating facioscapulohumeral muscular dystrophy
#2655RNA complexes that inhibit melanin production
#2656Polycomb-associated non-coding RNAs
#2657Method of Treating Cancer by Inhibition of DNA Repair Proteins
#2658COMPOSITIONS AND METHODS FOR TREATMENT OF OVARIAN CANCER
#2659Dual targeting antisense oligonucleotides as apoptotic inhibtor therapeutic compostions and methods for their use in the treatment of cancer
#2660Compositions and methods for modulation of SMN2 splicing in a subject
#2661Method for prevention of colectomy
#2662RNA interference in skin indications
#2663Short interfering RNA (siRNA) analogues
#2664SiRNA targeting PRK2, which is hepatitis C virus therapeutic agent
#2665Modulation of prekallikrein (PKK) expression
#2666LIPID FORMULATED DSRNA TARGETING THE PCSK9 GENE
#2667RNAi inhibition of alpha-ENaC expression
#2668Polycomb-associated non-coding RNAS
#2669Method of treating influenza A
#2670RNA interference mediated inhibition of hepatitis B virus (HBV) gene expression using short interfering nucleic acid (siNA)
#2671Modulation of transthyretin expression
#2672Compositions and their uses directed to huntingtin
#2673Compositions comprising synthetic polynucleotides encoding CRISPR related proteins and synthetic sgRNAs and methods of use
#2674Site-specific delivery of nucleic acids by combining targeting ligands with endosomolytic components
#2675Methods and compositions for modulating alpha-1 antitrypsin expression
#2676Oligonucleotide compounds for treatment of preeclampsia and other angiogenic disorders
#2677Aptamer construct
#2678Potent LNA oligonucleotides for the inhibition of HIF-1A expression
#2679RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases
#2680miR-29 mimics and uses thereof
#2681miR-155 inhibitors for treating cutaneous T cell lymphoma (CTCL)
#2682Polycomb-associated non-coding RNAs
#2683Modulation of Exon Recognition in Pre-mRNA By Interfering with the Secondary RNA Structure
#2684Oligonucleotide compounds for targeting huntingtin mRNA
#2685Polycomb-associated non-coding RNAs
#2686Compositions and Methods for Inhibition of PCSK9 Genes
#2687Compositions and methods for inhibiting expression of the PCSK9 gene
#2688CpG oligonucleotide analogs containing hydrophobic T analogs with enhanced immunostimulatory activity
#2689Antisense design
#2690Compositions and methods for inhibiting gene expression of Hif2alpha
#2691Compounds of chemically modified oligonucleotides and methods of use thereof
#2692Modulation of signal transducer and activator of transcription 3 (STAT3) expression
#2693MODULATION OF TRANSTHYRETIN EXPRESSION
#2694Ketohexokinase (KHK) iRNA compositions and methods of use thereof
#2695Treatment of vascular endothelial growth factor (VEGF) related diseases by inhibition of natural antisense transcript to VEGF
#26965′ triphosphate oligonucleotide with blunt end and uses thereof
#2697STAT3 inhibitors and uses thereof
#2698Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
#26995′ triphosphate oligonucleotide with blunt end and uses thereof
#2700Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes